| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Tvardi Therapeutics, Inc.$3.28
-0.54 (-14.21%)
D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
33.49 M
EPS
-1.58
P/E Ratio
-
Value Trade
169.28 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
4.91 M
Operating CF
-5.86 M
Total Assets
25.82 M
Total Liabilities
11.31 M
Equity
14.51 M
D/E Ratio
12,345
-7.99 %
Week
12.26 %
1 Month
0 %
3 Month
-6.79 %
6 Month
-99.26 %
5 Year
-99.15 %
All Time
Cash Data
Cash Position
24.98 M
Monthly Burn
1.95 M
Runway
10.9 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
2.76 M
52 Week Range
2.75 - 43.65
% held by Insiders
35.17 %
% held by Institutions
28.82 %
Enterprise Value
8.68 M
Total Shares
9.39 M
Short %
9.32 %
Float Shares
5.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tvardi Therapeutics, Inc.
430Total events
6Upcoming
168Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 6
Event history 424
Jul 7, 2026
Jun 5, 2026
Jun 4, 2026
Jun 2026
◆Topline ReadoutTTI-109Clinical Data
TTI-109 Phase 1 healthy volunteer topline data
healthy volunteersource ↗
Q2 2026
◆Topline ReadoutTTI-101Clinical Data
HCC Phase 1b/2 topline data expected in 1H:2026
Hepatocellular Carcinomasource ↗
Apr 14, 2026
Q2 2026
◆Topline ReadoutTTI-101Clinical Data
TTI-101 Phase 1b/2 HCC topline data
hepatocellular carcinoma (HCC)source ↗
Q2 2026
◆Topline ReadoutTTI-109Clinical Data
Healthy volunteer study results for TTI-109
healthy volunteerssource ↗
Q2 2026
◆Timing GuidancePresentation
Combined company expected to have cash runway into second half of 2026
Drug Pipeline Intelligence
D31
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 37%
Micro Cap (rank 575 of 911)
Percentile RankTvardi Therapeutics, Inc. faces pipeline headwinds (31/100), with $76M risk-adjusted pipeline value, led by TTI-101 in Idiopathic Pulmonary Fibrosis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TTI-101 Small molecule | Idiopathic Pulmonary Fibrosis | Phase 2 | NCT05671835 | 8% | $76M | COMPLETED | 100 | - | - | Aug 14, 2025 | - | Sep 30, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TTI-109 | — | Phase 1 | 2026-07-07 | reductions of up to 60% in STAT3-driven immune cell populations; diarrhea events with TTI-109 were similar in duration, transient, and resolved without treatment interruption; diarrhea events with TTI-109 were substantially shorter in duration (0.46 vs. 3.35 days) Read More | Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement Read More | |
TTI-109 | — | Phase 1 | 2026-07-07 | reductions of up to 60% in STAT3-driven immune cell populations; diarrhea events with TTI-109 were similar in duration, transient, and resolved without treatment interruption; diarrhea events with TTI-109 were substantially shorter in duration (0.46 vs. 3.35 days) Read More | Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement Read More | |
TTI-109 | — | Phase 1 | 2026-07-07 | reductions of up to 60% in STAT3-driven immune cell populations; diarrhea events with TTI-109 were similar in duration, transient, and resolved without treatment interruption; diarrhea events with TTI-109 were substantially shorter in duration (0.46 vs. 3.35 days) Read More | Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TVRD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TVRD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TVRD▲ +54.2%on this news· ran to +149% by day 1
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Tvardi Therapeutics announced positive Phase 1 results for TTI-109, a next-generation STAT3 inhibitor. The study confirmed TTI-109's rapid conversion to TTI-101, improved tolerability, and significant reductions in disease-relevant immune cell populations. The company plans to advance TTI-109 into dermatologic and gastrointestinal diseases, pending funding and regulatory approvals.
Read more →TVRD▼ -6.8%on this news
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics has announced its participation in two upcoming investor events, including the Jefferies Global Healthcare Conference and the Raymond James BioPharma CEO Strategy Series. The events will feature fireside chats and one-on-one meetings, providing an opportunity for management to discuss their clinical-stage therapies targeting STAT3. Webcasts of the events will be available for replay on the company's investor website.
Read more →TVRDTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics reported its Q1 2026 financial results, highlighting progress in its clinical trials. The company anticipates topline data from its next-generation STAT3 inhibitor, TTI-109, in June 2026, and is on track for results from the Phase 2 trial of TTI-101 in hepatocellular carcinoma in the second half of 2026. Despite a net loss, Tvardi expects its cash runway to support operations through late 2026.
Read more →TVRDTvardi Therapeutics Announces First Quarter
Tvardi Therapeutics has reported its Q1 2026 financial results, indicating a net loss of $6.8 million. The company is approaching crucial milestones, with topline data from its STAT3 inhibitor TTI-109 expected in June 2026. Furthermore, data from the ongoing Phase 2 trial of TTI-101 in hepatocellular carcinoma is projected for the second half of 2026. Tvardi's cash runway is deemed sufficient to support operations into Q4 2026.
Read more →TVRDTvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14th, 2026. The company focuses on developing novel therapies targeting STAT3 for inflammatory and proliferative diseases. Their ongoing clinical trials include TTI-101 for hepatocellular carcinoma and TTI-109 in healthy volunteers.
Read more →TVRD▼ -5.7%on this newsshared move
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics reported its fourth quarter and full-year 2025 results, highlighting key upcoming clinical milestones for its STAT3 inhibitors TTI-109 and TTI-101. The company anticipates topline data from a Phase 2 trial in hepatocellular carcinoma in H2 2026 and has sufficient cash to fund operations through Q4 2026. Despite a reduction in net loss, operational expenses have increased due to merger-related costs.
Read more →TVRDTvardi Therapeutics to Participate in Upcoming Investor Conferences
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in several upcoming investor conferences. These include the JonesTrading C-Suite Fireside Chat, Oppenheimer Healthcare Conference, TD Cowen Health Care Conference, and Barclays Global Healthcare Conference. The company aims to showcase its novel therapies targeting STAT3 for fibrosis-driven diseases.
Read more →TVRDOverview January 2026 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, inc
Tvardi Therapeutics has highlighted its upcoming clinical milestones, including the Phase 1 trial results for TTI-109 and topline results for TTI-101 in hepatocellular carcinoma (HCC). The company emphasizes the potential of its investigational therapies targeting STAT3 to offer disease-modifying effects. While encouraging preliminary data have been noted, the company acknowledges the inherent risks and uncertainties in clinical research, particularly in cross-study comparisons. Results from various ongoing trials are anticipated in 1H 2026, with a focus on enhancing treatment options in fibrosis-driven diseases.
Read more →TVRD▲ +7.6%on this news
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tvardi Therapeutics will present new data from its Phase 2 REVERT IPF clinical trial at the 44th Annual J.P. Morgan Healthcare Conference. The data shows encouraging results regarding TTI-101's effects on fibrosis and pulmonary function. The presentation is scheduled for January 15, 2026, in San Francisco, CA.
Read more →TVRD▲ +8.7%on this newsshared move
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
Tvardi Therapeutics has reported further findings from its Phase 2 REVERT IPF trial of TTI-101 for idiopathic pulmonary fibrosis (IPF). The data indicate a 9.4% reduction in fibrosis scores among TTI-101 patients versus a 2.4% decline in the placebo group. Additionally, 63% of patients treated with TTI-101 showed improvements in lung function, specifically forced vital capacity (FVC), compared to 46% in the placebo group. Despite some positive indicators, the trial did not initially meet all its stated goals. Tvardi is also progressing with a Phase 1 study on TTI-109, a next-generation STAT3 inhibitor, projected to provide further insights in 2026.
Read more →TVRDOverview November 2025 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, in
Tvardi Therapeutics, ticker TVRD, is conducting pioneering research focused on the inhibition of STAT3 for treating fibrotic diseases and hepatocellular carcinoma. The company reported a strong financial position with $36.5 million in cash, sufficient to fund operations through the end of 2026. Upcoming clinical milestones in 2026 include results from the TTI-109 Phase 1 trial and TTI-101's Phase 2 trial in HCC. Positive animal model data suggests that TTI-101 may effectively modulate immune responses and reduce fibrosis, positioning it as a promising candidate in the biopharma space.
Read more →TVRDTvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 Results from healthy volunteer st
Tvardi Therapeutics has announced its financial results for the third quarter of 2025 and provided an update on its clinical activities. The company is awaiting topline data from its Phase 2 trial of TTI-101 in hepatocellular carcinoma set for H1 2026, while also advancing its next-generation inhibitor TTI-109. Despite a net loss of $5.5 million, Tvardi's current cash resources are expected to fund operations through Q4 2026. The firm expresses confidence in the therapeutic potential of its products amid ongoing trials and operational adjustments.
Read more →TVRD▼ -83.9%on this news
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis HOUSTON, TX
Tvardi Therapeutics has released preliminary results from its Phase 2 REVERT trial for TTI-101 in patients with idiopathic pulmonary fibrosis (IPF). The trial did not meet its primary objectives, showing no significant efficacy compared to placebo, despite the treatment arms having comparable baseline characteristics. Notably, there were higher rates of discontinuation due to gastrointestinal adverse events in the treatment groups. Tvardi plans to conduct further analyses to understand these results and inform future steps.
Read more →TVRDTvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway a
Tvardi Therapeutics reported its financial results for the second quarter of 2025, highlighting significant advancements in its clinical trials. The company is preparing for topline data from its Phase 2 REVERT IPF trial, expected in Q4 2025. Additionally, interim data from another trial indicated meaningful activity for its lead product, TTI-101, in treating liver cancer. The company also stated that its current cash runway is sufficient to fund its operations into Q4 2026.
Read more →TVRD▼ -5.6%on this news
Overview June 2025 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, includ
The presentation discusses the forward-looking prospects of TTI-101, an investigational drug targeting STAT3 in fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). Initial data suggest TTI-101 may effectively reverse fibrosis and restore lung function in IPF. The drug also demonstrates promising results in HCC, showing encouraging trends in monotherapy and in combination treatments. Key data catalysts are expected soon, including Phase 2 unblinded results in 2025 and topline results for HCC trials in 2026.
Read more →TVRD▲ +14.8%on this news
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis Topline data from the REVERT IPF trial anticipated in 4Q 2025 HOUSTON, TX
Tvardi Therapeutics has completed enrollment for its Phase 2 clinical trial of TTI-101, a therapy targeting idiopathic pulmonary fibrosis (IPF). The trial, known as REVERT IPF, aims to evaluate the drug's safety and efficacy. Results are expected in the fourth quarter of 2025. TTI-101 is noted for its dual mechanism of action, potentially offering a new approach to treating a disease currently lacking effective therapies. The company emphasizes the unmet medical need for treatments that can halt or reverse fibrosis in IPF patients.
Read more →TVRDTvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update Completed merger with Cara Therapeutics; cash, cash equivalents and short-term investments at closing anticipated to be sufficient to
Tvardi Therapeutics reported its first quarter results for 2025 following the successful merger with Cara Therapeutics. The company expects its cash reserves will adequately support operations until at least the second half of 2026. Tvardi is on track for multiple Phase 2 data readouts, primarily targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma. Upcoming milestones include a planned IND submission for TTI-109 and anticipated topline data from clinical trials in 2025 and 2026.
Read more →TVRDTvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a clinical-stage biopharmaceutical company focused on developing treatments for fibrosis-driven diseases. The combined entity will trade under the ticker 'TVRD' starting April 16, 2025. Tvardi expects to have sufficient cash to fund operations into the second half of 2026 and anticipates key Phase 2 clinical data readouts in the near future.
Read more →TVRDOverview April 2025 This presentation and any accompanying oral commentary have been prepared by Tvardi Therapeutics, Inc. (“Tvardi”) for informational purposes only and not for any other purpose. All state
Tvardi Therapeutics, Inc. presented an update on their investigational drugs, TTI-101 and TTI-109, targeting STAT3 for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). The data indicated potential to reverse fibrosis and restore lung function, with details suggesting encouraging outcomes in both monotherapy and combination therapy approaches. Importantly, topline data from ongoing clinical trials are anticipated soon, which could significantly impact treatment landscapes for these conditions.
Read more →TVRDTvardi Therapeutics, Inc. INDEX TO FINANCIAL STATEMENTS Page Report of independent registered public accounting firm F-2 Balance sheets as of
Tvardi Therapeutics, Inc. reported its financial statements for the years ended December 31, 2024, and 2023, audited by Deloitte & Touche LLP. The financial position indicates recurring losses and insufficient liquidity to support ongoing operations. This raises concerns about the company's viability as it may not be able to continue as a going concern. Specific challenges in estimating research and development liabilities were also highlighted in the audit report.
Read more →TVRDTvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research
Tvardi Therapeutics announced the publication of Phase 1 study results for TTI-101 in patients with advanced solid tumors in the journal Clinical Cancer Research. The study reported promising antitumor activity, particularly in patients with hepatocellular carcinoma who are resistant to existing treatments. Importantly, the drug showed a reduction in the activated form of its target, STAT3, in tumor biopsies. Following these results, Tvardi is advancing TTI-101 into Phase 2 clinical trials for idiopathic pulmonary fibrosis and liver cancer.
Read more →TVRDTvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, will participate in the TD Cowen 45th Annual Health Care Conference from March 3 to 5, 2025, at the Marriott Copley Place in Boston, MA. This conference will feature various presentations and discussions about the health care industry, with Tvardi's management hosting one-on-one investor meetings during the event. The company's focus on developing oral therapies targeting STAT3 highlights its commitment to addressing fibrosis-driven diseases.
Read more →TVRDOverview January 2025 2 Disclaimer and Forward Looking Statements This presentation and any accompanying oral commentary have been prepared by Tvardi Therapeutics, Inc. (" Tvardi ") for informational purposes only and no
Tvardi Therapeutics, Inc. is set to merge with Cara Therapeutics to enhance its development of therapies targeting fibrosis-driven diseases. The merger, anticipated to close in the first half of 2025, will create a combined entity named Tvardi Therapeutics, Inc., with a pro forma ownership structure favoring Tvardi. This strategic move aims to leverage the resources and expertise of both companies to advance their promising drug candidates through various stages of clinical development. Additionally, the merged company is expected to be well capitalized, addressing financial needs through existing funds and anticipated cash reserves from the merger.
Read more →TVRDCara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibr
Cara Therapeutics and Tvardi Therapeutics have entered into a definitive merger agreement to form a Nasdaq-listed company focused on developing novel treatments targeting STAT3 for fibrosis-driven diseases. This merger, alongside a completed private financing of approximately $28 million, is expected to secure sufficient funds for the combined entity until the latter half of 2026. Tvardi anticipates reporting significant clinical data from Phase 2 programs beginning in late 2025. The leadership of both companies underscores the potential for significant advancements in treatment options for underserved patient populations.
Read more →TVRDCara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica - Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo - - Company
Cara Therapeutics announced that the Phase 2/3 KOURAGE-1 study evaluating oral difelikefalin for notalgia paresthetica did not yield meaningful benefits compared to placebo. As a result, the company will discontinue the clinical program for this indication. Despite prior proof-of-concept results, the lack of efficacy has led to disappointment among the company’s leadership, prompting a shift towards exploring strategic alternatives. The oral formulation remained well tolerated with a safety profile consistent with earlier trials.
Read more →TVRDCara Therapeutics Reports First Quarter 2024 Financial Results - Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24
Cara Therapeutics reported its financial results for Q1 2024, highlighting significant progress in its clinical program for notalgia paresthetica (NP). The company anticipates topline efficacy and safety results from the KOURAGE 1 Part A study by the end of Q2 2024, reflecting a solid commitment to addressing the unmet needs of patients. Despite facing increased net losses and a reduced cash balance, the firm maintains a belief in the potential of its differentiated asset, oral difelikefalin, and is prioritizing NP for its future developments.
Read more →TVRDCara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results -Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)- -Com
Cara Therapeutics reported its financial results for the fourth quarter and full year 2023, emphasizing a strategic pivot towards the late-stage development of oral difelikefalin for notalgia paresthetica. The company completed the enrollment of the KOURAGE 1 Part A study ahead of schedule and anticipates reporting topline results in the third quarter of 2024. Nevertheless, it faced a net loss of $118.5 million for 2023, and total revenue decreased significantly compared to the previous year. Cara maintains a cash runway into 2026, which is crucial for advancing its clinical programs.
Read more →TVRDCara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 - Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need - -
Cara Therapeutics announced a strategic shift to concentrate on its oral difelikefalin Phase 2/3 program focused on notalgia paresthetica, a neuropathic disorder. This decision will lead to the discontinuation of its advanced chronic kidney disease program and a planned workforce reduction. The company aims to extend its cash runway into 2026, which is expected to help achieve key milestones in the notalgia paresthetica program. Cara Therapeutics reported an enrollment progress ahead of projections in its ongoing clinical trials for this condition.
Read more →TVRDCara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis - Oral difelikefalin as adjunct to topical cor
Cara Therapeutics has announced the outcome of the KIND 1 study's dose-finding Part A, indicating that oral difelikefalin as adjunct therapy to topical corticosteroids did not show a meaningful clinical benefit when compared to corticosteroids alone. Consequently, the company will discontinue its clinical program in pruritus associated with atopic dermatitis. However, Cara continues to pursue other late-stage clinical programs for this treatment in different indications, which remain on schedule with data readouts expected in the second half of 2024.
Read more →TVRDCorporate Presentation November 2023 2 Forward - Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" withi n the meaning of the
Cara Therapeutics provided a corporate presentation outlining its forward-looking statements regarding the commercialization of KORSUVA injection and oral difelikefalin. The company is focusing on the unmet need for treatments targeting chronic pruritus, with KORSUVA being the first FDA-approved product specifically for chronic kidney disease-associated pruritus. Despite its achievements, Cara acknowledges risks with commercial partnerships and clinical trials, which could impact future outcomes.
Read more →TVRDCara Therapeutics Reports Third Quarter 2023 Financial Results - Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 - - Key data readouts for all three
Cara Therapeutics reported its financial results for Q3 2023, highlighting a non-dilutive financing agreement with HealthCare Royalty for up to $40 million that extends its cash runway into 2025. The company expects key data readouts from its late-stage oral difelikefalin clinical programs, including the KIND 1 atopic dermatitis trial, with topline results anticipated in December. Despite achieving $4.9 million in revenue, the company also reported an increased net loss compared to the previous year, indicating financial challenges moving forward.
Read more →TVRDCara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected t
Cara Therapeutics has announced a non-dilutive financing agreement with HealthCare Royalty totaling up to $40 million. This funding is aimed at advancing their late-stage clinical programs for oral difelikefalin, which targets pruritus associated with conditions like atopic dermatitis and chronic kidney disease. The agreement includes an initial payment of $17.5 million, with an additional $20 million depending on pricing milestones in Germany. Milestone payments are also reliant on the performance of KORSUVA in Japan.
Read more →TVRDCorporate Presentation August 2023 2 Forward - Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" withi n the meaning of the Pr
Cara Therapeutics provided a corporate presentation detailing their ongoing efforts to commercialize KORSUVA and Kapruvia, drugs aimed at treating chronic pruritus associated with chronic kidney disease. The company highlighted the strong clinical data supporting its product candidates, especially oral difelikefalin, which shows promise in managing itch in a variety of conditions. Additionally, they discussed the importance of their partnerships and the upcoming regulatory submissions for their product pipeline. However, the presentation noted inherent risks in product commercialization and reliance on partners' performance.
Read more →TVRDCara Therapeutics Reports Second Quarter 2023 Financial Results - 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA (difelikefalin) injection - - Demand fo
Cara Therapeutics has announced its financial results for the second quarter of 2023, reporting total revenues of $6.9 million, primarily driven by collaborative revenue from its KORSUVA injection. The company noted a significant acceleration in demand, with a 46% quarterly increase in vial orders. Additionally, the Centers for Medicare & Medicaid Services proposed a new reimbursement rule favorable for KORSUVA following its TDAPA period, with expectations for a final ruling in Q4 2023. Despite the positives, the company recorded a substantial net loss of $31.5 million, with ongoing investments in R&D impacting financial stability.
Read more →TVRDCara Therapeutics Appoints Helen M. Boudreau to Board of Directors
Cara Therapeutics, Inc. announced the appointment of Helen M. Boudreau to its Board of Directors. With over 30 years of experience in the biotechnology and pharmaceutical sectors, Boudreau is expected to guide the company's commercial strategy for KORSUVA and the clinical development of oral difelikefalin. Her previous roles include Chief Operating Officer at the Bill & Melinda Gates Medical Research Institute and CFO positions at notable companies like Novartis and Pfizer. This strategic addition aims to enhance Cara's efforts in treating chronic pruritus.
Read more →TVRDCorporate Presentation May 2023 2 Forward - Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" withi n the meaning of the Priva
Cara Therapeutics provided an update on its corporate presentation, focusing on its KORSUVA injection and Kapruvia. KORSUVA is notably the first FDA approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients. The company is actively working on expanding Difelikefalin's reach to treat moderate to severe pruritus in patients with advanced non-dialysis CKD and atopic dermatitis. The company highlighted its strong partnerships and positive clinical data while acknowledging the inherent risks of commercialization and regulatory approval processes.
Read more →TVRDCara Therapeutics Reports First Quarter 2023 Financial Results - 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA (difelikefalin) injection - - Accelerati
Cara Therapeutics reported its financial results for the first quarter of 2023, with total revenues reaching $6.2 million, driven largely by KORSUVA injection. The company noted a significant acceleration in demand, with vial sales more than doubling since the previous quarter. Their late-stage oral difelikefalin clinical programs are progressing as planned, with an internal readout expected in Q4 2023. However, the company reported a slight increase in net loss compared to the prior year, amid a decrease in cash reserves.
Read more →TVRDCorporate Presentation March 2023 2 Forward - Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" withi n the meaning of the Pri
Cara Therapeutics has presented its corporate update for March 2023, highlighting its forward-looking statements regarding the commercialization of its products KORSUVA and Kapruvia. KORSUVA, now the first FDA-approved treatment for chronic pruritus associated with chronic kidney disease in hemodialysis patients, is supported by a substantial commercial partnership aimed at enhancing its market reach. The company is also exploring oral formulations of difelikefalin for broader applications in treating chronic pruritus across various patient populations. Potential future growth remains contingent upon the successful navigation of clinical trials and regulatory approvals.
Read more →TVRDCara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results - 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company's share of profit of KORSUVA (difelik
Cara Therapeutics announced its financial results for the fourth quarter and full year of 2022, reporting total revenue of $3.3 million for Q4 and $41.9 million for the full year. The company highlighted strong initial sales for KORSUVA injection, with encouraging feedback from users. However, it also faced a net loss of $30.3 million in Q4. Looking ahead, Cara expects an acceleration of product launches in Europe and regulatory decisions in Japan in the coming months.
Read more →TVRDJ.P. Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference highlighted Cara Therapeutics’ advancements in treating chronic pruritus with its products, KORSUVA injection and oral difelikefalin. KORSUVA is the first product approved for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in hemodialysis patients. The company has formed a strong commercial partnership with Fresenius to enhance sales efforts, and ongoing clinical trials show promise for oral difelikefalin in addressing further indications. Cara Therapeutics continues to pursue regulatory approval for expanding its treatment offerings.
Read more →TVRDCara Therapeutics Reports Third Quarter 2022 Financial Results - Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA (difelikefalin) injection - - Strong demand for KORSUVA injection dr
Reports Third Quarter 2022 Financial Results was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA (difelikefalin) injection - demand for KORSUVA injection driven by large dialysis organizations with ~180,000 vials shipped - scheduled in 4Q22 to discuss po
Read more →TVRDCara Therapeutics NOVEMBER 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the meaning of the Private Se
Cara Therapeutics NOVEMBER 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Examples of these
Read more →TVRDCara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors STAMFORD, Conn., November 3, 2022 - Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Read more →TVRDCara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
Appoints Ryan Maynard as Chief Financial Officer STAMFORD, Conn., Sept. 12, 2022 - Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced th
Read more →TVRDCara Therapeutics Reports Second Quarter 2022 Financial Results - Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA (difelikefalin) injection and a $15M milestone payment from the E
Reports Second Quarter 2022 Financial Results was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia (difelikefalin) - Phase 2 trial met primary endpo
Read more →TVRDCara Therapeutics CORPORATE PRESENTATION AUGUST 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the mean
Cara Therapeutics CORPORATE PRESENTATION AUGUST 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
Read more →TVRDCara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica - Study achieved primary endpoint of Worst Itch-N
Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) - Onset of action seen a
Read more →TVRDCara Therapeutics Reports First Quarter 2022 Financial Results KORSUVA (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia (difelikefalin) approved by European Com
Cara Therapeutics Reports First Quarter 2022 KORSUVA (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with c
Read more →TVRDCara Therapeutics CORPORATE PRESENTATION MARCH 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the meani
Cara Therapeutics CORPORATE PRESENTATION MARCH 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results KORSUVA (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of
Reports Fourth Quarter and Full Year 2021 Financial Results KORSUVA (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dep
Read more →TVRDCara Therapeutics J.P. MORGAN 2022 CHRISTOPHER A. POSNER PRESIDENT & CEO Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking stateme
Cara Therapeutics J.P. MORGAN 2022 CHRISTOPHER A. POSNER PRESIDENT & CEO Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the meaning of the Private Securities Litigatio
Read more →TVRDCara Therapeutics Announces CMS Grants TDAPA to KORSUVA (difelikefalin) Injection KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 Stamford, Conn.
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA (difelikefalin) Injection KORSUVA receives TDAPA reimbursement beginning U.S. commercial launch on track for early second Stamford, Conn. Dec. 20, 2021 - Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U
Read more →TVRDCara Therapeutics Reports Third Quarter 2021 Financial Results - KORSUVA (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis
Therapeutics Reports Third Quarter 2021 Financial Results - KORSUVA (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) - - Chris
Read more →TVRDCara Therapeutics Announces CEO Transition - Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to laun
Cara Therapeutics Announces CEO Transition - Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA (difelikefalin) injection for the treatment of
Read more →TVRDCara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients First and only therapy approved b
Stamford, Conn. and St. Gallen, Switzerland, 23 August 2021 - Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus a
Read more →TVRDTargeting Pruritus with First - In - Class Therapeutics AUGUST 12 TH , 2021 2 Confidential. For internal use only. Forward Looking Statements Statements contained in this presentation regarding matters that are not histo
Targeting Pruritus with First - In - Class Therapeutics AUGUST 12 TH , 2021 2 Confidential. For internal use only. Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward - looking statements" within the m
Read more →TVRDCara Therapeutics Reports Second Quarter 2021 Financial Results - New Drug Application (NDA) Filing for KORSUVA Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Da
Reports Second Quarter 2021 Financial Results - New Drug Application (NDA) Filing for KORSUVA Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, - Conference call today at 4:30 p.m. ET STAMFORD, Conn., Aug
Read more →TVRDCara Therapeutics Reports First Quarter 2021 Financial Results - U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA Injection in CKD-aP - - Conference
Reports First Quarter 2021 Financial Results - U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA Injection in CKD-aP - - Conference call today at 4:30 p.m. ET STAMFORD, Conn., May 10, 2021 - Cara Therapeu
Read more →TVRDCara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus - Study did not meet Primary Endpoint of worst-itch NRS chan
Announces Topline Results From Dose-Ranging Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus - Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in th
Read more →TVRDVFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin Companies have successfully submitted the EU regulatory appli
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin St.Gallen, Switzerland, and Stamford, Conn., 30 March 2021 - Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutic
Read more →TVRDCara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA * injection in hemodialysis patients with moderate-to-severe pruritus FDA has set Prescription Drug Use
Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA * injection in hemodialysis patients with moderate-to-severe pruritus Stamford, Conn, and St. Gallen, Switzerland, March 8, 2021 -Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results - U.S. FDA Accepts NDA Filing for KORSUVA Injection in CKD-aP - - Conference call today at 4:30 p.m. ET
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results - U.S. FDA Accepts NDA Filing for KORSUVA Injection in CKD-aP - - Conference call today at 4:30 STAMFORD, Conn., February 25, 2021 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical com
Read more →TVRDCara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus - First NDA submission for Company's lead program, KORSU
Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA Injection in Hemodialysis Patients with Moderate-to-Severe STAMFORD, Conn., Dec. 28, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializin
Read more →TVRDCara Therapeutics Reports Third Quarter 2020 Financial Results - Conference call toda y at 4:30 p.m. ET
Reports Third Quarter 2020 Financial Results Conference call today at 4:30 p.m. ET - STAMFORD, Conn., November 9, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate p
Read more →TVRDVifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva * to treat dialysis patients with pruritus Vifor Pharma secures commercial rights for IV Korsuva in non-Fresenius Medical Care dia
Pharma and Cara Therapeutics sign US license agreement for IV Korsuva * to treat dialysis patients with pruritus to Host Conference Call Today at 8:30am EDT - Conn. and St Gallen, October 20, 2020 - Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that b
Read more →TVRDCara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
Therapeutics Appoints Thomas Reilly as Chief Financial Officer STAMFORD, Conn., Oct. 1, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus
Read more →TVRDCara Therapeutics Reports Second Quarter 2020 Financial Results - Conference call today at 4:30 p.m. ET
Reports Second Quarter 2020 Financial Results Conference call today at 4:30 p.m. ET - Conn., August 10, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by
Read more →TVRDCara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus - Patient enrollment increased approximately
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus STAMFORD, Conn., June 17, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company
Read more →TVRDCara Therapeutics Reports First Quarter 2020 Financial Results - Conference call today at 4:30 p.m. ET
Cara Therapeutics Reports First Quarter 2020 Financial Results - Conference call today at 4:30 STAMFORD, Conn., May 11, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle
Read more →TVRDCara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVA TM Injection in Hemodialysis Patients with Pruritus - Statistically significan
Cara Therapeutics and Vifor Fresenius Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection Hemodialysis Patients with Pruritus significant improvement in primary endpoint of proportion of patients with three point or greater reducti
Read more →TVRDCara Therapeutics Reports Clinical Updates - On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA Injection in second quarter - - On track to complete interim statistical analysis for ongoing Phase
Therapeutics Reports Clinical Updates On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA Injection in second quarter - On track to complete interim statistical analysis for ongoing Phase 2 trial of Oral KORSUVA in atopic dermatitis in second quarter Tim
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results - Conference call today at 4:30 p.m. ET
Reports Fourth Quarter and Full Year 2019 Financial Results - Conference call today at 4:30 STAMFORD, Conn., February 27, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to all
Read more →TVRDTargeting Pruritus with Novel Peripherally - Restricted Kappa Agonist Therapeutics JP Morgan Healthcare Conference January 2020 Forward Looking Statements 2 This presentation contains certain forward - looking statements
Targeting Pruritus with Novel Peripherally - Restricted Kappa Agonist Therapeutics JP Morgan Healthcare Conference January 2020 Forward Looking Statements 2 This presentation contains certain forward - looking statements within the meaning of the Private Securities Litigation Re
Read more →TVRDTargeting Pruritus with Novel Peripherally - Restricted Kappa Agonist Therapeutics December 2019 Forward Looking Statements 2 This presentation contains certain forward - looking statements within the meaning of the Priv
Targeting Pruritus with Novel Peripherally - Restricted Kappa Agonist Therapeutics December 2019 Forward Looking Statements 2 This presentation contains certain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases
Read more →TVRDCara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus - Met primary endpoint with statistically significant reduction in
Cara Therapeutics Announces Positive Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus - Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs place
Read more →TVRDCara Therapeutics Reports Third Quarter 2019 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Third Quarter 2019 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., November 5, 2019 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to
Read more →TVRDCara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence Oral Formulation Technology - Peptelligence technology currently used in Oral KORSUVA formulation
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence Oral Formulation Technology STAMFORD, Conn., August 21, 2019 Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing
Read more →TVRDCara Therapeutics Reports Second Quarter 2019 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Second Quarter 2019 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., August 7, 2019 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to
Read more →TVRDCara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock STAMFORD, Conn., July 24, 2019 Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate
Read more →TVRDCara Therapeutics Announces Proposed Offering of Common Stock
Cara Therapeutics Announces Proposed Offering of Common Stock STAMFORD, Conn., July 24, 2019 Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by sele
Read more →TVRDCara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA TM Injection in Hemodialysis Patients with Pruritus - Statistically significant improvement in primary endpoint of proportion of p
Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVATM Hemodialysis Patients with Pruritus - Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching in
Read more →TVRDCara Therapeutics Reports First Quarter 2019 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports First Quarter 2019 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., May 7, 2019 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Conference call today at 4:30 p.m. ET STAMFORD, Conn., March 12, 2019 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary
Read more →TVRDCara Therapeutics Reports Third Quarter 2018 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Third Quarter 2018 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., November 6, 2018 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed t
Read more →TVRDCara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer - Former VP of Medical Affairs for Dermatology at Celgene to lead development of KORSUVA in dermatological conditions
Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer - Former VP of Medical Affairs for Dermatology at Celgene to lead development of KORSUVA in dermatological conditions - STAMFORD, Conn., Oct 23, 2018 Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmac
Read more →TVRDCara Therapeutics Reports Second Quarter 2018 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Second Quarter 2018 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., August 7, 2018 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to
Read more →TVRDCara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock STAMFORD, Conn., July 18, 2018 Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate
Read more →TVRDCara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery -I.V. CR845 achieved statistical significance for the study s primary endpoint of pain
Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery -I.V. CR845 achieved statistical significance for the study s primary endpoint of pain relief over the 0 to 24-hour (AUC 0-24) period post-surg
Read more →TVRDCara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA Injection in Dialysis Patients with Pruritus Cara receives upfront payment of $50 m
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA Injection in Dialysis Patients with Pruritus Cara receives upfront payment of $50 million in cash and an equity investment of $20 million C
Read more →TVRDCara Therapeutics Reports First Quarter 2018 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports First Quarter 2018 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., May 9, 2018 Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to all
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, Conn., March 15, 2018 Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities d
Read more →TVRDCara Therapeutics Reports Third Quarter 2017 Financial Results Management to host conference call today at 4:30 p.m.
Cara Therapeutics Reports Third Quarter 2017 Financial Results Management to host conference call today at 4:30 p.m. ET STAMFORD, Conn., November 2, 2017 Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entit
Read more →TVRDCara Therapeutics Reports Second Quarter 2017 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Second Quarter 2017 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, CONN., August 3, 2017 Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alle
Read more →TVRDCara Therapeutics Reports First Quarter 2017 Financial Results - Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruri
Cara Therapeutics Reports First Quarter 2017 Financial Results - Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruritus - Completed public offering of common stock, raising
Read more →TVRDCara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus Met primary endpoint with 68% reduction in worst itching scores versus placebo
Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus Met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (p<0.0019) Met secon
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, CONN., March 9, 2017 Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities de
Read more →TVRDCara Therapeutics Reports Third Quarter 2016 Financial Results Currently enrolling three late stage studies with CR845 totaling over 900 patients Top line data expected in 1H 2017 Conference call today at 4:30 p.m.
Cara Therapeutics Reports Third Quarter 2016 Financial Results Currently enrolling three late stage studies with CR845 totaling over 900 patients Top line data expected in 1H 2017 Conference call today at 4:30 p.m. ET STAMFORD, CONN., November 3, 2016 Cara Therapeutics, Inc.
Read more →TVRDCara Therapeutics Reports Second Quarter 2016 Financial Results - Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain - Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis
Cara Therapeutics Reports Second Quarter 2016 Financial Results Conference call today at 4:30 p.m. ET STAMFORD, CONN., August 4, 2016 Cara Therapeutics, Inc. (NASDAQ: CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities
Read more →TVRDCara Therapeutics Reports First Quarter 2016 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports First Quarter 2016 Financial Results Conference call today at 4:30 p.m. ET SHELTON, CONN., May 5, 2016 Cara Therapeutics, Inc. (NASDAQ: CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities desig
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results Conference call today at 4:30 p.m.
Cara Therapeutics Reports Fourth Quarter and Full Year 2015 Conference call today at 4:30 p.m. ET SHELTON, CONN., March 10, 2016 Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviat
Read more →TVRDForward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any
Novel Peripheral Kappa Opioid Product Candidates: Efficacy Without Opioid Side Effects JPM Healthcare Conference January, 2016 Exhibit 99.1 Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
Read more →TVRDCara Therapeutics Reports Third Quarter 2015 Financial Results Initiated Phase 3 program for I.V. CR845 in acute postoperative pain Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients Earned $2.75M in miles
Cara Therapeutics Reports Third Quarter 2015 Financial Results Initiated Phase 3 program for I.V. CR845 in acute postoperative pain Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients Earned $2.75M in milestone payments for clinical development of uremic pruritus
Read more →TVRDCara Therapeutics Reports Second Quarter 2015 Financial Results Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus Completed successful public offering of co
Cara Therapeutics Reports Second Quarter 2015 Financial Results Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus Completed successful public offering of common stock, raising net proceeds of $75.1 million First P
Read more →TVRDCara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity
Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity Trial demonstrated statistically significant results on se
Read more →TVRDCara Therapeutics Reports First Quarter 2015 Financial Results - End-of-Phase 2 meeting with FDA informs Phase 3 clinical development program for novel kappa opioid, I.V. CR845 - - - Conference call today at 4:30pm ET SH
Cara Therapeutics Reports First Quarter 2015 Financial Results - End-of-Phase 2 meeting with FDA informs Phase 3 clinical development program for novel kappa opioid, I.V. CR845 - - Conference call today at SHELTON, CONN., May 12th, 2015 Cara Therapeutics, Inc. (NASDAQ: CARA),
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results Phase 3 pivotal trials for I.V. CR845 expected to initiate during second quarter of 2015, following scheduled End-of-Phase-2 Meeting Reported
Cara Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results Phase 3 pivotal trials for I.V. CR845 expected to initiate during second quarter of 2015, following scheduled End-of-Phase-2 Meeting Reported positive top-line data from human abuse liability trial of
Read more →TVRDCara Therapeutics Reports Third Quarter 2014 Financial Results Reported positive top-line data from human abuse liability trial for I.V. CR845 - Phase 3 registration trials for I.V. CR845 expected to initiate in early 20
Cara Therapeutics Reports Third Quarter 2014 Financial Results Reported positive top-line data from human abuse liability trial for I.V. CR845 - Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015 Conference call today at 4:30pm ET SHELTON, CONN., No
Read more →TVRDCara Therapeutics Reports Second Quarter 2014 Financial Results Conference call today at 4:30pm ET SHELTON, CONN .
Cara Therapeutics Reports Second Quarter 2014 Financial Results Conference call today at 4:30pm ET SHELTON, CONN., August 7, 2014 Cara Therapeutics, Inc. (NASDAQ: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to all
Read more →TVRDCara Therapeutics Reports First Quarter 2014 Financial Results - Conference call today at 4:30pm ET SHELTON, CONN .
Cara Therapeutics Reports First Quarter 2014 Financial Results - Conference call today at 4:30pm ET SHELTON, CONN., May 12, 2014 Cara Therapeutics, Inc. (NASDAQ: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle
Read more →TVRDCara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results - Conference call today at 4:30pm ET - SHELTON, CONN .
Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results - Conference call today at 4:30pm ET - SHELTON, CONN., March 27, 2014 Cara Therapeutics, Inc. (NASDAQ: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entit
Read more →Competitive Position
How TVRD ranks across every disease it competes inCompetitive Position is a premium feature
See how TVRD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial